サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1544103

前臨床イメージング（In-VIVO）の世界市場

Preclinical Imaging (In-VIVO)

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
前臨床イメージング（In-VIVO）の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

前臨床イメージング（In-VIVO）の世界市場は2030年までに14億米ドルに達する見込み

2023年に10億米ドルと推定された前臨床イメージング（In-VIVO）の世界市場は、2030年には14億米ドルに達し、分析期間2023-2030年のCAGRは4.8%で成長すると予測されます。本レポートで分析したセグメントの1つである前臨床イメージングモダリティは、CAGR 5.2％を記録し、分析期間終了時には9億10万米ドルに達すると予測されています。前臨床イメージング試薬セグメントの成長率は、分析期間中CAGR 4.2%と推定されます。

米国市場は2億7,870万米ドルと推定、中国はCAGR4.6％で成長すると予測

米国の前臨床イメージング（In-VIVO）市場は、2023年に2億7,870万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 4.6%で推移し、2030年までに2億2,520万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.6%と3.8%と予測されています。欧州では、ドイツがCAGR 4.1%で成長すると予測されています。

世界の前臨床イメージング（In-VIVO）市場- 主要動向と促進要因まとめ

前臨床イメージング（In-VIVO）：バイオメディカル調査の進展

前臨床イメージング（In-VIVO）とは、主に生物医学研究を目的として、生きた動物モデルで生物学的プロセスを可視化し調査するための高度なイメージング技術の使用を指します。この画像診断は、ヒトを対象とした臨床試験の前に行われ、研究者が疾患のメカニズムを理解し、新薬の有効性を評価し、治療効果をリアルタイムでモニタリングするのに役立っています。前臨床研究で使用される一般的なイメージング法には、磁気共鳴画像法（MRI）、陽電子放射断層撮影法（PET）、コンピュータ断層撮影法（CT）、生物発光や蛍光イメージングなどの光学イメージング技術があります。前臨床イメージングの重要性は、健康や疾病の根底にある生物学的プロセスに対する詳細な洞察を提供し、研究者が医薬品開発やその他の生物医学研究分野において十分な情報に基づいた意思決定を行えるようにする能力にあります。病気の進行や治療効果を非侵襲的にモニタリングできる前臨床イメージングは、医学の進歩において重要な役割を果たしています。

技術の進歩はどのように前臨床イメージング（In-VIVO）を向上させているか？

技術の進歩は前臨床イメージングの能力を著しく向上させ、画像モダリティの解像度と機能の両方を強化しています。高磁場MRI磁石や高感度PET検出器などのイメージングハードウェアの革新により、画像の空間的・時間的解像度が向上し、生物学的プロセスをより詳細に可視化できるようになった。PET/CTやMRI/PETなど2つ以上のイメージング技術を組み合わせたマルチモーダルイメージングシステムの開発により、研究者は同時に補完的なデータを取得できるようになり、疾病メカニズムや治療効果についてより包括的な理解が得られるようになった。標的造影剤や放射性トレーサーを含む分子イメージング薬剤の進歩は、イメージングの特異性を向上させ、特定の分子経路や細胞プロセスの可視化を可能にしました。さらに、人工知能（AI）や機械学習アルゴリズムを画像解析に統合することで、複雑な画像データの処理・解釈能力が向上し、より正確で効率的な研究成果が得られるようになった。このような技術的向上により、前臨床イメージングの応用範囲と影響力が拡大し、生物医学研究に不可欠なツールとなっています。

前臨床イメージング（In-VIVO）の主な用途と利点は？

前臨床イメージング（In-VIVO）は様々な研究分野で使用されており、病気の理解や新しい治療法の開発を促進する多くのメリットを提供しています。腫瘍学研究では、前臨床イメージングにより腫瘍の成長や転移を非侵襲的に追跡することができ、研究者がリアルタイムでがん治療の有効性を評価するのに役立っています。神経科学では、MRIやPETなどの画像技術が脳の構造と機能の研究に用いられ、アルツハイマー病やパーキンソン病などの神経疾患に関する洞察を提供しています。心臓血管の研究は、心臓や血管の機能を可視化することで前臨床イメージングの恩恵を受け、心臓病の研究や新しい心臓血管薬の開発に役立っています。さらに、前臨床イメージングは、体内での薬物の分布や作用をモニターする薬物動態学や薬力学の研究にも用いられています。前臨床イメージングの主な利点は、生物学的プロセスを非侵襲的にリアルタイムでモニタリングできること、縦断的な調査による動物使用の削減、臨床研究に役立つ高解像度データの生成などです。これらの利点により、前臨床イメージングは現代の生物医学研究において重要な要素となっています。

前臨床イメージング（In-VIVO）市場の成長を促進する要因は？

前臨床イメージング（In-VIVO）市場の成長は、いくつかの要因によってもたらされています。前臨床イメージングが臨床研究や医薬品開発に重要な情報を提供するため、より正確で非侵襲的な方法で疾病メカニズムを調査し、薬効を評価したいという要求が高まっていることが大きな原動力となっています。また、イメージング・モダリティの解像度、感度、機能性を向上させる技術の進歩も市場成長を後押ししています。製薬およびバイオテクノロジー産業の拡大、特に個別化医療の分野が、前臨床イメージングツールの需要増加に寄与しています。さらに、研究における動物使用の削減が重視されるようになり、前臨床イメージングが同じ動物で長期的な研究を可能にすることと相まって、市場の普及をさらに後押ししています。AIや機械学習を含む高度なデータ分析技術の統合は、前臨床イメージングの有用性を高め、その継続的な成長を後押ししています。これらの要因は、イメージング技術の継続的な革新と相まって、前臨床イメージング（In-VIVO）市場の持続的な成長を後押ししています。

調査対象企業の例（全38件）

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP14177

Global Preclinical Imaging (In-VIVO) Market to Reach US$1.4 Billion by 2030

The global market for Preclinical Imaging (In-VIVO) estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.4 Billion by 2030, growing at a CAGR of 4.8% over the analysis period 2023-2030. Preclinical Imaging Modalities, one of the segments analyzed in the report, is expected to record a 5.2% CAGR and reach US$900.1 Million by the end of the analysis period. Growth in the Preclinical Imaging Reagents segment is estimated at 4.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$278.7 Million While China is Forecast to Grow at 4.6% CAGR

The Preclinical Imaging (In-VIVO) market in the U.S. is estimated at US$278.7 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$225.2 Million by the year 2030 trailing a CAGR of 4.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.6% and 3.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.1% CAGR.

Global Preclinical Imaging (In-VIVO) Market - Key Trends and Drivers Summarized

Preclinical Imaging (In-VIVO): Advancing Biomedical Research

Preclinical imaging (in-vivo) refers to the use of advanced imaging techniques to visualize and study biological processes in live animal models, primarily for biomedical research purposes. This imaging is conducted before clinical trials in humans, helping researchers understand disease mechanisms, evaluate the efficacy of new drugs, and monitor treatment effects in real-time. Common imaging modalities used in preclinical research include magnetic resonance imaging (MRI), positron emission tomography (PET), computed tomography (CT), and optical imaging techniques such as bioluminescence and fluorescence imaging. The importance of preclinical imaging lies in its ability to provide detailed insights into the biological processes underlying health and disease, enabling researchers to make informed decisions in drug development and other areas of biomedical research. By allowing non-invasive monitoring of disease progression and treatment response, preclinical imaging plays a crucial role in the advancement of medical science.

How Are Technological Advancements Enhancing Preclinical Imaging (In-VIVO)?

Technological advancements have significantly improved the capabilities of preclinical imaging, enhancing both the resolution and functionality of imaging modalities. Innovations in imaging hardware, such as higher-field MRI magnets and more sensitive PET detectors, have increased the spatial and temporal resolution of images, allowing for more detailed visualization of biological processes. The development of multimodal imaging systems, which combine two or more imaging techniques (e.g., PET/CT or MRI/PET), has enabled researchers to simultaneously capture complementary data, providing a more comprehensive understanding of disease mechanisms and treatment effects. Advances in molecular imaging agents, including targeted contrast agents and radiotracers, have improved the specificity of imaging, allowing for the visualization of specific molecular pathways and cellular processes. Additionally, the integration of artificial intelligence (AI) and machine learning algorithms into image analysis has enhanced the ability to process and interpret complex imaging data, facilitating more accurate and efficient research outcomes. These technological improvements have expanded the applications and impact of preclinical imaging, making it an indispensable tool in biomedical research.

What Are the Key Applications and Benefits of Preclinical Imaging (In-VIVO)?

Preclinical imaging (in-vivo) is used in various research areas, offering numerous benefits that advance the understanding of disease and the development of new treatments. In oncology research, preclinical imaging allows for the non-invasive tracking of tumor growth and metastasis, helping researchers evaluate the effectiveness of cancer therapies in real-time. In neuroscience, imaging techniques such as MRI and PET are used to study brain structure and function, providing insights into neurological disorders such as Alzheimer's disease and Parkinson's disease. Cardiovascular research benefits from preclinical imaging through the visualization of heart and blood vessel function, aiding in the study of heart disease and the development of new cardiovascular drugs. Additionally, preclinical imaging is used in pharmacokinetics and pharmacodynamics studies to monitor the distribution and action of drugs within the body. The primary benefits of preclinical imaging include the ability to conduct non-invasive, real-time monitoring of biological processes, the reduction of animal use through longitudinal studies, and the generation of high-resolution data that can inform clinical research. These advantages make preclinical imaging a critical component of modern biomedical research.

What Factors Are Driving the Growth in the Preclinical Imaging (In-VIVO) Market?

The growth in the preclinical imaging (in-vivo) market is driven by several factors. The increasing demand for more precise and non-invasive methods to study disease mechanisms and evaluate drug efficacy is a significant driver, as preclinical imaging provides critical insights that inform clinical research and drug development. Technological advancements that enhance the resolution, sensitivity, and functionality of imaging modalities are also propelling market growth. The expansion of the pharmaceutical and biotechnology industries, particularly in the area of personalized medicine, is contributing to the increased demand for preclinical imaging tools. Additionally, the growing emphasis on reducing animal use in research, coupled with the ability of preclinical imaging to enable longitudinal studies in the same animals, is further boosting market adoption. The integration of advanced data analysis techniques, including AI and machine learning, is enhancing the utility of preclinical imaging, driving its continued growth. These factors, combined with the ongoing innovation in imaging technologies, are driving the sustained growth of the preclinical imaging (in-vivo) market.

Select Competitors (Total 38 Featured) -

  • Aspect Imaging Ltd.
  • Bruker Corp.
  • Idex Health & Science LLC
  • Mauna Kea Technologies
  • Mediso Ltd.
  • Milabs B.V.
  • Miltenyi Biotech GmbH
  • MR Solutions
  • New England Biolabs
  • PerkinElmer, Inc.
  • Siemens A.G.
  • Trifoil Imaging, Inc.
  • FujiFilm VisualSonics, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Preclinical Imaging (In-VIVO) - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Technological Advancements in Imaging Modalities Propel Market Growth
    • Rising Prevalence of Chronic Diseases Expands Addressable Market Opportunity
    • Growing Adoption of Multimodal Imaging Solutions Throws the Spotlight on Innovation
    • Focus on Drug Discovery and Development Accelerates Market Dynamics
    • Expansion of Contract Research Organizations (CROs) Boosts Market Prospects
    • Increasing Use of Imaging in Oncology Research Propels Market Expansion
    • Adoption of AI and Machine Learning in Image Analysis Drives Market Dynamics
    • Focus on Non-invasive Imaging Techniques Sustains Market Growth
    • Growing Investments in Preclinical Studies for Rare Diseases Expands Market Reach
    • Focus on Improving Image Resolution and Accuracy Enhances Market Opportunities
    • Regulatory Support for Preclinical Research Activities Propels Market Dynamics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Preclinical imaging modalities by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Preclinical imaging modalities by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Preclinical imaging reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Preclinical imaging reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Preclinical Imaging (In-VIVO) Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • JAPAN
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • CHINA
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: China 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • EUROPE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Preclinical Imaging (In-VIVO) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • FRANCE
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: France 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • GERMANY
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 41: Rest of Europe Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Rest of Europe Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: Rest of Europe 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Preclinical Imaging (In-VIVO) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 44: Asia-Pacific Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Asia-Pacific Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Asia-Pacific 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 47: Rest of World Recent Past, Current & Future Analysis for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Rest of World Historic Review for Preclinical Imaging (In-VIVO) by Segment - Preclinical imaging modalities and Preclinical imaging reagents Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Rest of World 16-Year Perspective for Preclinical Imaging (In-VIVO) by Segment - Percentage Breakdown of Value Sales for Preclinical imaging modalities and Preclinical imaging reagents for the Years 2014, 2024 & 2030

IV. COMPETITION